Research Use Only Notice:
This article discusses Cartalax only as a laboratory research reagent.The concentrations, calculations, test methods, and study results below apply only to controlled laboratory research.
They must not be used as instructions for human use, veterinary use, home preparation, or any other non-research purpose.
In this article, Cartalax means the tripeptide Ala-Glu-Asp, shortened to AED. The target chemical entity is H-L-Ala-L-α-Glu-L-Asp-OH, with a free N-terminus and a free C-terminal carboxyl group.

The abbreviation AED denotes the residue order but does not, by itself, confirm stereochemistry, Glu linkage type, terminal modifications, or salt form.
ChEBI and PubChem list AED as a three-amino-acid peptide with the molecular formula C12H19N3O8, an average molecular mass of about 333.30 g/mol, and a monoisotopic neutral mass of 333.11721 Da.[1][2]
AED must not be confused with AEDG, AEDL, AEDP, or any other longer peptide. These compounds contain different amino-acid sequences and are different chemical substances.
Peptides with the same amino acids in a different order may also have the same molecular formula and mass, so molecular weight alone is not enough to confirm the sequence.
Basic Identity
| Item | Information |
|---|---|
| Name used in this article | Cartalax |
| Chemical entity | H-L-Ala-L-α-Glu-L-Asp-OH (free N-terminus, free C-terminus, three L-residues) |
| One-letter sequence | AED (denotes residue order only; does not specify stereochemistry or terminal form) |
| Number of amino acids | 3 |
| Molecular formula | C12H19N3O8 |
| Average molecular mass | Approximately 333.30 g/mol; monoisotopic neutral mass 333.11721 Da[1] |
| Chemical form | The supplier should state whether the material is the free peptide, a salt, or a peptide containing a specific counterion. |
| CAS number | Some commercial databases and suppliers report CAS 85806-95-7, but this article has not independently confirmed this registration number in publicly accessible authoritative chemical registries. Any CAS number used in product records should be verified through the batch COA and an authoritative chemical registry. |
| Purity | There is no single purity value that applies to every batch. Use the batch-specific HPLC result and, when available, the separate peptide-content result. |
| Storage | General peptide-handling guidance for MS peptide standards recommends storing lyophilized peptides frozen, dry, and tightly sealed, commonly between −20°C and −80°C. This is not an AED-specific stability conclusion. The batch-specific storage instructions and stability data should take priority.[3] |
| Solubility | A fixed quantitative solubility value should not be assumed. Solubility can change with concentration, pH, buffer, salt form, and counterion. It should be checked with a small laboratory test for the actual batch. |
General storage advice is not the same as an AED-specific stability study.
Once the peptide is dissolved, the laboratory should set a storage period based on actual stability data.
Repeated freeze–thaw cycles should be avoided by using suitable aliquots.[3]
What the Rat Cell Study Found
A 2023 laboratory paper studied AED and a cartilage-derived polypeptide complex in primary chondrocyte cultures from rats.
The cells came from young rats aged 3 months and older rats aged 20 months.
Cell growth was measured at passage 4 over five days.
AED was tested at 20, 200, and 2,000 ng/mL.[4]
The authors reported that 200 ng/mL was the concentration associated with the clearest increase in cell number.
Compared with untreated cells, the reported increase was about 1.4–1.8 times in cultures from young rats
and about 1.6–2.1 times in cultures from older rats.[4]
These results show only that more cells were counted under the conditions used in that cell-culture study.
The study did not show that AED rebuilt intact cartilage, restored joint function, changed a disease process,
or produced the same result in a whole-animal model.[4]
The study also should not be described as proving that a higher concentration always gives a larger response.
The paper tested three concentrations and reported 200 ng/mL as the main working concentration.
Each laboratory should confirm the concentration range in its own cells, medium, passage number, and assay.
What the Study Did Not Measure
The rat chondrocyte paper focused on cell growth.
It did not directly measure AED binding to DNA, movement into the cell nucleus, or direct control of specific cartilage genes.
It also did not report a complete set of measurements for COL2A1, ACAN, SOX9, MMP-9, MMP-13, PCNA, p53, p16, or p21
in the same chondrocyte experiment.[4]
Results from other peptides, other cell types, or cartilage-derived peptide mixtures should not be added to this study
and presented as if they were all measured with AED in rat chondrocytes.
What Is Known About the Proposed Mechanism
Some papers from the short-peptide research field discuss possible interactions between peptides and DNA.
However, the main papers often cited for this idea did not directly test AED in rat chondrocytes.
A 2013 paper used computer modeling to study Lys-Glu and Ala-Glu-Asp-Gly, also called AEDG,
with selected DNA promoter sequences.
AEDG has four amino acids and is not the same compound as the three-amino-acid AED peptide.[5]
A separate 2006 paper studied the interaction of AEDG with a synthetic double-stranded DNA system.
It also did not test AED in chondrocytes.[6]
For this reason, direct DNA binding by Cartalax should be described as an unconfirmed idea.
It should not be written as a proven mechanism unless an AED-specific study directly measures cell uptake,
nuclear location, DNA binding, and the resulting change in gene activity.
Laboratory Concentrations
Laboratory Configuration Warning:
The concentrations below are cell-culture concentrations only.
They are not human or veterinary doses and must not be converted into any administration instructions.
The following conversions assume anhydrous free-peptide AED at 100% net peptide content (monoisotopic neutral mass 333.11721 Da).
When preparing solutions from lyophilized material, correct the weighed mass using the lot-specific peptide content or assay value from the COA.
HPLC area purity alone must not be substituted for the peptide-content correction factor.[1][4]
| Mass Concentration | Approximate Molar Concentration |
|---|---|
| 20 ng/mL | 60 nM |
| 200 ng/mL | 600 nM |
| 2,000 ng/mL | 6.0 µM |
The basic calculation is:
Molarity (mol/L) = mass concentration (g/L) × peptide-content fraction ÷ molecular mass (g/mol)
Dilutions can be calculated with:
C1V1 = C2V2
Do not directly pipette a volume below the reliable range of the laboratory pipette.
Prepare an intermediate working solution when needed.
Record the solvent, pH, concentration, preparation date, storage condition, and number of freeze–thaw cycles.
How to Read a Cartalax COA
A certificate of analysis, or COA, describes the test results for one batch.
It should not be treated as proof that the material is suitable for every experiment.
It also does not prove safety or effectiveness outside laboratory research.
FDA Q6A guidance defines a specification as a list of tests, test procedures, and acceptance limits.
FDA Q2(R2) explains that an analytical method should be validated for the purpose for which it is used.
These documents are cited here only for general laboratory quality principles.
They do not mean that Cartalax is an approved product.[7][8]
| COA Item | What It Should Tell the Laboratory |
|---|---|
| Product identity | The chemical entity should be identified as H-L-Ala-L-α-Glu-L-Asp-OH (free N-terminus, free C-terminus, all L-residues, standard α-peptide bonds). A different sequence or stereochemical form must be treated as a different compound. |
| Batch number | The COA and the vial should show the same batch or lot number. |
| HPLC result | The COA should state the HPLC method, the main-peak area percentage, and preferably include the chromatogram. HPLC area percentage is method-dependent and should not automatically be called total peptide content. |
| Mass spectrometry | For the free, non-isotopically labelled AED tripeptide, the theoretical monoisotopic neutral mass is 333.11721 Da. Common theoretical ions in positive-ion mode include [M+H]+ at approximately m/z 334.1245; in negative-ion mode, [M−H]− at approximately m/z 332.1099. The COA should state the observed m/z, ion form, charge state, mass error (ppm or Da), instrument type, and whether the reported mass is deconvoluted. A matching intact mass supports molecular-mass identity but may not prove the amino-acid order or stereochemistry. |
| Sequence confirmation | For the AED tripeptide, sequence confirmation is best supported by LC-MS/MS with sufficient fragment-ion coverage, Edman degradation, NMR, or an orthogonal method validated to distinguish sequence isomers and stereoisomers. Intact mass alone or a single HPLC retention time is not sufficient to confirm the complete sequence and stereochemistry. |
| Peptide content | When available, this result gives a better estimate of the actual peptide amount than HPLC area percentage alone. The reporting basis (as-is, anhydrous, counterion-free, or peptide-equivalent) should be stated. |
| Water | Water content or loss on drying should be reported separately because water can add to the weighed material mass. |
| Counterion | The COA should identify and, when relevant, measure the counterion or salt form. |
| Residual solvents | Residual solvents should be listed separately from HPLC peptide purity and checked against the stated batch specification. |
| Microbiological tests | Sterility, bioburden, and endotoxin are separate tests. HPLC and mass spectrometry do not establish these properties. |
| Storage and retest date | The COA should state storage conditions and any retest or expiry information supported by the supplier. |
A historical FDA inspection reference document notes that no single identity test may be sufficient in every case and
lists methods such as HPLC, amino-acid analysis, sequencing, peptide mapping, and mass spectrometry
as different tools that can provide different types of identity information.
That document was written primarily for biotechnology-derived products; it is cited here only to illustrate the general principle of orthogonal identity confirmation and is not a specific quality standard for synthetic tripeptides.[9]
Basic Study Controls
A simple cell-culture study should include controls that help separate an AED-related result from normal culture variation.
- Untreated control:
Cells grown under the same conditions without AED. - Vehicle control:
Cells receiving the same amount of solvent or buffer used for the AED solution. - Concentration range:
More than one concentration, including concentrations below and above the planned working level. - Time points:
More than one measurement time when the study question requires it. - Viability test:
A separate check that helps show whether changes in cell number are linked to toxicity. - Sequence control:
A peptide with the same amino-acid composition in a different order when testing whether the AED sequence itself matters. - Independent samples:
Separate biological samples where the model allows them. - Planned analysis:
The main endpoint and statistical method should be chosen before the results are reviewed.
An increase in cell number does not automatically mean that the cells kept a normal cartilage-cell state
or produced more cartilage matrix.
Those questions need separate measurements.
Evidence Limits
The clearest direct evidence used in this article is a single published rat chondrocyte culture study.
The two mechanism papers discussed above studied AEDG or other short peptides rather than AED in rat chondrocytes.[4][5][6]
For this reason, the evidence should be described in simple, limited terms:
AED was reported to increase cell number in one rat chondrocyte culture study under specific laboratory conditions.
The current evidence does not support statements such as:
- “Cartalax repairs cartilage.”
- “Cartalax restores joints.”
- “Cartalax reverses cartilage aging.”
- “Cartalax has been proven to enter the cell nucleus.”
- “Cartalax directly switches cartilage genes on or off.”
- “A high HPLC percentage proves the material is safe.”
References
- European Bioinformatics Institute.
ChEBI: Ala-Glu-Asp, CHEBI:158137 (C12H19N3O8, avg 333.297, mono 333.11721 Da, H-L-Ala-L-α-Glu-L-Asp-OH).
https://www.ebi.ac.uk/chebi/CHEBI:158137 - National Center for Biotechnology Information.
PubChem Compound Summary: Alanyl-glutamyl-aspartic acid, CID 87815447.
https://pubchem.ncbi.nlm.nih.gov/compound/Alanyl-glutamyl-aspartic-acid - Hoofnagle AN, Whiteaker JR, Carr SA, et al.
Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays.
Clin Chem. 2016;62(1):48-69. doi:10.1373/clinchem.2015.250563.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4830481/ - Myakisheva SN, Linkova NS, Polyakova VO, Ryzhak GA.
Peptides of Cartilage Tissue: Regulation of Chondrocyte Proliferation, Geroprotection and Prospects for Use in Osteoarthrosis.
Vrach. 2023;34(10):46-49. doi:10.29296/25877305-2023-10-09.
https://journals.eco-vector.com/0236-3054/article/view/117604/en_US - Khavinson VK, Tarnovskaya SI, Linkova NS, Pronyaeva VE, Shataeva LK, Yakutseni PP.
Short Cell-Penetrating Peptides: A Model of Interactions with Gene Promoter Sites.
Bull Exp Biol Med. 2013;154(3):403-410. doi:10.1007/s10517-013-1961-3.
https://pubmed.ncbi.nlm.nih.gov/23484211/ - Khavinson VK, Solovyov AY, Shataeva LK.
Molecular Mechanism of Interaction Between Oligopeptides and Double-Stranded DNA.
Bull Exp Biol Med. 2006;141(4):457-461. doi:10.1007/s10517-006-0198-9.
https://pubmed.ncbi.nlm.nih.gov/17152370/ - U.S. Food and Drug Administration.
Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q6a-specifications-test-procedures-and-acceptance-criteria-new-drug-substances-and-new-drug-products - U.S. Food and Drug Administration.
Q2(R2) Validation of Analytical Procedures.
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q2r2-validation-analytical-procedures - U.S. Food and Drug Administration.
Biotechnology Inspection Guide (1991).
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/biotechnology-inspection-guide-1191
Research Use Only Disclaimer
Research Use Only:
The Cartalax product described on this page is supplied for laboratory research use only and is not intended for human or veterinary use.
This article is provided for informational context regarding published laboratory research and general analytical and handling considerations,
and does not constitute medical, clinical, veterinary guidance or treatment advice.